LOGIN  |  REGISTER
Assertio

Syra Health Secures Nursing Contract with North Carolina Department of Public Safety

June 12, 2024 | Last Trade: US$0.40 0.02 5.99

CARMEL, Ind., June 12, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, announced today it has been awarded a contract with the North Carolina Department of Public Safety, Division of Juvenile Justice and Delinquency Prevention to provide statewide nursing services. The contract is effective for one year, with two additional one-year renewal options.

Under the contract, Syra Health will supply temporary nursing staff to Youth Development Centers and Juvenile Detention Centers across North Carolina. The roles include registered nurses, licensed practical nurses, medical technicians, and certified nursing assistants to provide for the medical needs of youth in the custody of the Department of Public Safety. The revenue generated by the contract is based on both the number of positions to be filled and the duration of each.

The Syra Health-provided clinical healthcare staff will be responsible for screening and evaluating youth upon admission, developing healthcare plans, and providing appropriate interventions.

"We are honored to work with government agencies to provide essential healthcare services," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "Our team is committed to delivering the highest quality of care and support across the nation."

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company that is powering better health in challenging areas such as behavioral and mental healthdigital health, and population health, by providing innovative and meaningful solutions. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health serves everyone working in healthcare. For more information, visit www.syrahealth.com.

FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:

Christine Drury

Communications and Marketing Director

Syra Health

463-345-5180

This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:

Ben Shamsian

Vice President

Lytham Partners, LLC

646-829-9701

This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB